DiscoveryBioMed, Inc. (DMB) has discovered and is currently developing a new class of small molecule monotherapy that utilizes the pathophysiological features of cystic fibrosis and works on two drug targets. In Cystic Fibrosis, patients’ production of the CFTR protein and ENaC ion channel is abnormal, leading to a dysfunctional CFTR activity and over-activity of ENaC.
The residential apartment brand MCLife, which belongs to MC Companies, is launching the #CFShoeSelfie campaign, with the main purpose of raising awareness about the chronic disease cystic fibrosis (CF). At a time when emails, social media, television, and advertisements bombard everyone with images that are easily forgotten, the company aims…
Pharmaceutical company PARI Pharma received marketing authorization from the European Commission for its nebulizer Vantobra, a breakthrough therapy for patients who suffer from cystic fibrosis (CF). The product is a novel and highly concentrated tobramycin therapeutic option for inhalation that uses a Tolero nebulizer, and will now be commercialized in…
Travel Lake Anna might look like a typical travel agency dedicated to promoting vacations around Lake Anna, a state park located in Virginia. However, the company has a unique business model and purpose. Husband and wife team Chris and Laura Denkers created and manage the company in support of their two sons who were…
AffloVest, a wearable, self-contained oscillation vest device from International Biophysics that helps patients with Cystic Fibrosis breathe easier, was previously backed by numerous patient testimonies and is now proven in a new Clinical Study that it increased forced expiratory volume in one second (FEV1) an average…
A study led by researchers at the University of Szeged in Hungary recently revealed that excessive alcohol consumption impairs the function of the defective gene in cystic fibrosis (CF) leading to pancreatitis. The study was published in the journal Gastroenterology and is entitled “Alcohol…
A team led by researchers at the University Hospital in Strasbourg, France is currently recruiting patients for a clinical trial designed to assess the efficacy of combined lung and pancreatic islet transplantation in individuals with end-stage cystic fibrosis (CF). The trial is entitled “Metabolic…
Researchers at the University of Michigan Medical School recently published in the journal Microbiome findings indicating that lung microbiota alterations observed during disease onset in individuals with cystic fibrosis may become useful as predictors of exacerbations. The study is entitled “The daily dynamics of…
An article published in BioMed Central’s Pulmonary Medicine journal provides evidence that the impaired immune system, a key feature in cystic fibrosis (CF), may lead to patients being deprived of necessary oxygen due to lung tissue destruction. The study, entitled “Hypoxia down-regulates expression…
Biopharmaceutical company Aridis Pharmaceuticals, Inc. has named Paul-Andre de Lame, MD as its new chief medical officer to help the company in their efforts to develop new anti-infective and immune therapies to treat infectious diseases. Aridis is currently developing a reactive monoclonal antibody drug called Aerucin, to treat Pseudomonas aeruginosa associated with cystic fibrosis.
Visit the Cystic Fibrosis News Today forums to connect with others in the CF community.
Get regular updates to your inbox.